Showing 1 - 10 of 731
Persistent link: https://www.econbiz.de/10003885817
Persistent link: https://www.econbiz.de/10011333162
Persistent link: https://www.econbiz.de/10008758996
A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health...
Persistent link: https://www.econbiz.de/10012463320
By influencing the size and bargaining power of private insurers, public subsidization of private health insurance may project effects beyond the subsidized population. We test for such spillovers by analyzing how increases in insurer size resulting from the implementation of Medicare Part D...
Persistent link: https://www.econbiz.de/10011266983
Persistent link: https://www.econbiz.de/10008741247
Persistent link: https://www.econbiz.de/10008315213
A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health...
Persistent link: https://www.econbiz.de/10005027090
Public financing of private health insurance may generate external effects beyond the subsidized population, by influencing the size and bargaining power of health insurers. We test for this external effect in the context of Medicare Part D. We analyze how Part D-related insurer size increases...
Persistent link: https://www.econbiz.de/10008611557
Persistent link: https://www.econbiz.de/10008643999